

ASX RELEASE

Volpara Quarterly Results and Investor Conference Call

Wellington, NZ, 21st April 2020: [Volpara Health Technologies](#) ("Volpara"; ASX: VHT), a medical technology company whose cancer screening software platform assists in the delivery of personalized patient care, is pleased to advise it will release its Appendix 4C – Quarterly Cash Flow Statement for the period ended 31 March 2020 (Q4 FY20) on Thursday 23rd April 2020.

Investors are invited to join a conference call hosted by CEO Dr Ralph Highnam, CFO Craig Hadfield and CCO Mark Koeniguer, at 09:00am AEST (11:00am NZST) on Thursday 23rd April 2020.

To pre-register, please follow this link:

<https://s1.c-conf.com/diamondpass/10006065-invite.html>

You will receive a calendar notification with dial-in details and a PIN for fast-track access to the call.

If you are unable to use register in advance, then at the time of the conference you can call one of the numbers below and provide the **conference ID 10006065** to an operator.

AUSTRALIA:	1800558698
ALT. AUSTRALIA:	1800809971
OTHER INTERNATIONAL (METERED):	+61731454010
SYDNEY:	0290073187
NEW ZEALAND:	0800453055
AUCKLAND:	099291687
CHRISTCHURCH:	039742632
WELLINGTON:	049747738
BELGIUM:	080072111
CHINA:	4001200659
FRANCE:	0800981498
GERMANY:	08001827617
HONG KONG:	800966806
INDIA:	0008001008443
INDONESIA:	18030193275
IRELAND:	1800948625
ITALY:	800793500
JAPAN:	00531161281

MALAYSIA:	1800816294
NORWAY:	80069950
PHILIPPINES:	180011101462
SINGAPORE:	8001012785
SOUTH AFRICA:	0800999976
SOUTH KOREA:	00798142063275
SWEDEN:	020791959
SWITZERLAND:	0800820030
TAIWAN:	00801127397
THAILAND:	0018001562063275
UAE:	800035702705
UK:	08000518245
USA/CANADA:	18558811339
CHICAGO:	18153732080
LOS ANGELES:	19092354020
NEW YORK:	19142023258

ENDS.

For further information, please contact:

Ralph Highnam, CEO
Volpara Health Technologies
ralph.highnam@volparasolutions.com
t: +64 21 149 0541

Trevor Chappell
WE Buchan
tchappell@we-buchan.com
t: +61 3 9866 1215

ABOUT VOLPARA HEALTH TECHNOLOGIES LIMITED (ASX: VHT)

VHT is a MedTech SaaS company founded in 2009 on research originally conducted at Oxford University. VHT's clinical functions for screening clinics provide feedback on breast density, compression, dose, and quality, while its enterprise-wide practice software management helps with productivity, compliance, reimbursement, and patient tracking.

VHT's technology and services have been used by customers and/or research projects in 38 countries and are supported by numerous patents, trademarks, and regulatory clearances, including FDA clearance and CE marking. Since its listing on the ASX in April 2016, VHT has raised A\$95 million, including A\$55 million in June 2019. VHT is based in Wellington, New Zealand.

At the end of June 2019, VHT acquired MRS, a company based in Seattle, WA. MRS provides mammography reporting systems to over 1,600 breast clinics and hospitals, and to VHT a much stronger US presence, experienced local headquarters, and accelerated sales through cross-selling opportunities.

For more information, visit www.volparasolutions.com